Limited coverage criteria – ticagrelor

Last updated on March 24, 2025

Special Authority requests can now be submitted online. It's simple and quick!

This drug is eligible for automatic approval when patient meets criteria and the request is submitted by eForms

Generic name	ticagrelor
Strength & form	90 mg tablet

Special Authority criteria	Approval period
To be taken in combination with ASA 75 mg – 150 mg¹ daily for patients with acute coronary syndrome (i.e., ST elevation myocardial infarction [STEMI], non-ST elevation myocardial infarction [NSTEMI] or unstable angina with ONE of the following: Failure on optimal clopidogrel and ASA therapy as defined by definite stent thrombosis² or recurrent STEMI or NSTEMI or UA after revascularization with percutaneous coronary intervention (PCI) OR STEMI, NSTEMI or UA and undergoing revascularization via PCI Notes: Co-administration of ticagrelor with high-maintenance dose ASA (> 150 mg daily) is not recommended Definite stent thrombosis, according to the Academic Research Consortium, is defined as: a total occlusion originating in or within 5 mm of the stent OR a visible thrombus within the stent OR within 5 mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours Definite stent thrombosis must be confirmed by angiography or by pathologic evidence of acute thrombosis	Up to 12 months

Special Authority criteria

Approval period

To be taken in combination with ASA 75 mg – 150 mg¹ daily for patients with acute coronary syndrome (i.e., ST elevation myocardial infarction [STEMI], non-ST elevation myocardial infarction [NSTEMI] or unstable angina with ONE of the following:

Failure on optimal clopidogrel and ASA therapy as defined by definite stent thrombosis² or recurrent STEMI or NSTEMI or UA after revascularization with percutaneous coronary intervention (PCI)

STEMI, NSTEMI or UA and undergoing revascularization via PCI

Notes:

Co-administration of ticagrelor with high-maintenance dose ASA (> 150 mg daily) is not recommended
Definite stent thrombosis, according to the Academic Research Consortium, is defined as:
- a total occlusion originating in or within 5 mm of the stent OR
- a visible thrombus within the stent OR
- within 5 mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours
Definite stent thrombosis must be confirmed by angiography or by pathologic evidence of acute thrombosis

Up to 12 months

Practitioner exemptions

A Collaborative Prescribing Agreement (CPA) is available to a limited number of cardiologists and selected internal medicine specialists working in a cardiology capacity. These practitioners are not required to submit a Special Authority request form for coverage
The CPA is intended for prescribers caring for patients immediately before, during and immediately after PCI. To ensure uninterrupted coverage for patients, prescribers who sign a CPA must write prescriptions for ticagrelor for the full intended duration of therapy (i.e., up to 12 months)
PharmaCare coverage covers ticagrelor for patients who meet the limited coverage criteria and whose prescription has been written by the cardiologist or selected internal medicine specialist who has entered into a CPA
Each CPA must be signed by the cardiologist or selected internal medicine specialist working in a cardiology capacity who is requesting coverage (not a delegate)
Practitioners who have not signed a CPA may submit a Special Authority request if the patient meets the criteria above. These prescriptions will not be covered automatically

Special notes

Ticagrelor is contraindicated in patients with active pathological bleeding as well as in those with a history of intracranial hemorrhage and moderate to severe hepatic impairment

Special Authority request form(s)

Log in to eForms
HLTH 5395 – Ticagrelor (PDF, 292KB)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics